VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
Verrica Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.44−0.16 (-4.31%)
Close on Oct 19, 2026
- Market cap
- $73.29M
- P/E (TTM)
- –
- Dividend yield
- –
Verrica Pharmaceuticals Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $5.86M | $5.02M | – | – | $12.70M | $3.44M | – | – | – | – | – | – | 100.0% | -53.8% |
| Operating Segment | – | – | $5.09M | $14.34M | $12.70M | $3.44M | $344.00K | -$1.78M | $5.18M | $3.83M | – | – | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $5.09M | $4.29M | $3.72M | $3.61M | $4.53M | $3.42M | $315.00K | -$1.87M | $4.89M | $3.23M | $1.87M | $2.79M | 86.9% | +12.3% |
| License and collaboration revenue | $769.00K | $733.00K | $1.37M | $10.74M | $8.17M | $17.00K | $29.00K | $84.00K | $285.00K | – | – | – | 13.1% | -90.6% |
| License and Collaboration Revenue, Milestones | $0 | $0 | – | $10.00M | $8.00M | $0 | – | – | – | – | – | – | 0.0% | -100.0% |
| Collaboration [Member] | – | – | – | – | – | $17.00K | $29.00K | $84.00K | $285.00K | $594.00K | $122.00K | $125.00K | – | – |
| License and Collaboration Revenue, Commercial Supply and Development | – | $700.00K | $1.40M | $700.00K | – | $17.00K | $0 | $100.00K | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Verrica Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.